Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency approved Eisai Co., Ltd (OTC:ESAIY) (OTC:ESALF) and Biogen Inc’s (NASDAQ:BIIB) Leqembi (lecanemab). Lecanemab is indicated for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Also Read: Biogen/Eisai’s Alzheimer’s Drug Leqembi Gets ‘No Go’ From European Drug Regulator’s Advisory Panel, Cites Serious Side Events. Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD) that ta…
